BARDA backs GSK antibiotic with $94M in R&D support

The U.S. government's bioterror drug development arm, BARDA, has stepped up with a $94 million contract to support the development of a new gram-negative antibiotic in GlaxoSmithKline's ($GSK) pipeline. In-licensed from Anacor, GSK '052 now has ample R&D support over the next four years to back Phase II clinical trials for ventilator-associated pneumonia and Phase III trials for complicated intra-abdominal infections. "BARDA's financial support for the development of GSK '052 will help ensure the rapid development of this compound toward its approval in all relevant indications," said Anacor CEO David Perry. Release

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.